Stock Scorecard



Stock Summary for Biomarin Pharmaceutical Inc (BMRN) - $72.83 as of 3/28/2025 2:31:06 PM EST

Total Score

15 out of 30

Safety Score

57 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for BMRN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BMRN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BMRN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BMRN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BMRN (57 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 5
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BMRN

Femasys Inc. ( FEMY ) Reports Q4 Loss, Lags Revenue Estimates 3/27/2025 2:10:00 PM
5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction 3/27/2025 9:06:00 AM
BioMarin ( BMRN ) Up 4.2% Since Last Earnings Report: Can It Continue? 3/21/2025 3:30:00 PM
INCY Stock Down on Disappointing Skin Disease Study Data 3/18/2025 7:00:00 PM
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? 3/18/2025 3:40:00 PM
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer 3/17/2025 3:10:00 PM
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies 3/17/2025 1:38:00 PM
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan 3/13/2025 4:12:00 PM
Is BioMarin ( BMRN ) a Solid Growth Stock? 3 Reasons to Think "Yes" 3/12/2025 4:45:00 PM
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why 3/12/2025 4:37:00 PM

Financial Details for BMRN

Company Overview

Ticker BMRN
Company Name Biomarin Pharmaceutical Inc
Country USA
Description BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/22/2025

Stock Price History

Last Day Price 72.83
Price 4 Years Ago 88.35
Last Day Price Updated 3/28/2025 2:31:06 PM EST
Last Day Volume 1,364,582
Average Daily Volume 1,579,539
52-Week High 94.85
52-Week Low 60.63
Last Price to 52 Week Low 20.12%

Valuation Measures

Trailing PE 32.37
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 10.35
Free Cash Flow Ratio 12.22
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 5.33
Total Cash Per Share 5.96
Book Value Per Share Most Recent Quarter 29.66
Price to Book Ratio 2.46
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 4.87
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 16
Analyst Strong Buy Ratings 7

Share Statistics

Total Shares Outstanding 190,777,000
Market Capitalization 13,894,288,910
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.71%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 645.00%
Annual Earnings Growth 154.62%
Reported EPS 12 Trailing Months 2.25
Reported EPS Past Year 2.49
Reported EPS Prior Year 0.95
Net Income Twelve Trailing Months 426,859,000
Net Income Past Year 426,859,000
Net Income Prior Year 167,645,000
Quarterly Revenue Growth YOY 15.60%
5-Year Revenue Growth 11.11%
Operating Margin Twelve Trailing Months 34.40%

Balance Sheet

Total Cash Most Recent Quarter 1,137,706,000
Total Cash Past Year 1,137,706,000
Total Cash Prior Year 1,073,810,000
Net Cash Position Most Recent Quarter -57,432,000
Net Cash Position Past Year -57,432,000
Long Term Debt Past Year 1,195,138,000
Long Term Debt Prior Year 2,186,972,000
Total Debt Most Recent Quarter 1,195,138,000
Equity to Debt Ratio Past Year 0.83
Equity to Debt Ratio Most Recent Quarter 0.83
Total Stockholder Equity Past Year 5,657,990,000
Total Stockholder Equity Prior Year 4,951,549,000
Total Stockholder Equity Most Recent Quarter 5,657,990,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 475,423,000
Free Cash Flow Per Share Twelve Trailing Months 2.49
Free Cash Flow Past Year 475,423,000
Free Cash Flow Prior Year 51,648,000

Options

Put/Call Ratio 1.93
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.16
MACD Signal 1.23
20-Day Bollinger Lower Band 60.35
20-Day Bollinger Middle Band 66.62
20-Day Bollinger Upper Band 72.88
Beta 0.33
RSI 61.72
50-Day SMA 74.88
150-Day SMA 85.91
200-Day SMA 84.82

System

Modified 3/28/2025 7:32:23 PM EST